Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Omicron JN.1 Subvariant SARS-CoV-2 rS Vaccine (NVX-CoV2705)
NCT07079670Phase 3Completed
- Sponsor
- Sanofi
- Start
- Oct 2025
- Primary completion
- Jan 2026
- Countries
- 1
01
Overview
A Phase 3 trial of NVX-CoV2705 in coronavirus disease 2019 (COVID-19), sponsored by Sanofi. Started Oct 2025; status: completed.
02
Drugs
NVX-CoV2705
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07079670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07079670.